User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Plasmodium vivax morbidity after radical cure: A cohort study in Central Vietnam

Primary tabs

download
  • Open access
  • PDF
  • 2.07 M
Pham, Thanh Vinh Nguyen, Hong Van Rosas Aguirre, Angel [UCL] Nguyen, Van Van A. Cleves, Mario Speybroeck, Niko [UCL] Ashley, Elizabeth A

BACKGROUND: In Vietnam, the importance of vivax malaria relative to falciparum during the past decade has steadily increased to 50%. This, together with the spread of multidrug-resistant Plasmodium falciparum, is a major challenge for malaria elimination. A 2-year prospective cohort study to assess P. vivax morbidity after radical cure treatment and related risk factors was conducted in Central Vietnam. METHODS AND FINDINGS: The study was implemented between April 2009 and December 2011 in four neighboring villages in a remote forested area of Quang Nam province. P. vivax-infected patients were treated radically with chloroquine (CQ; 25 mg/kg over 3 days) and primaquine (PQ; 0.5 mg/kg/day for 10 days) and visited monthly (malaria symptoms and blood sampling) for up to 2 years. Time to first vivax recurrence was estimated by Kaplan-Meier survival analysis, and risk factors for first and recurrent infections were identified by Cox regression models. Among the 260 P. vivax patients (61% males [159/260]; age range 3-60) recruited, 240 completed the 10-day treatment, 223 entered the second month of follow-up, and 219 were followed for at least 12 months. Most individuals (76.78%, 171/223) had recurrent vivax infections identified by molecular methods (polymerase chain reaction [PCR]); in about half of them (55.61%, 124/223), infection was detected by microscopy, and 84 individuals (37.67%) had symptomatic recurrences. Median time to first recurrence by PCR was 118 days (IQR 59-208). The estimated probability of remaining free of recurrence by month 24 was 20.40% (95% CI [14.42; 27.13]) by PCR, 42.52% (95% CI [35.41; 49.44]) by microscopy, and 60.69% (95% CI [53.51; 67.11]) for symptomatic recurrences. The main risk factor for recurrence (first or recurrent) was prior P. falciparum infection. The main limitations of this study are the age of the results and the absence of a comparator arm, which does not allow estimating the proportion of vivax relapses among recurrent infections. CONCLUSION: A substantial number of P. vivax recurrences, mainly submicroscopic (SM) and asymptomatic, were observed after high-dose PQ treatment (5.0 mg/kg). Prior P. falciparum infection was an important risk factor for all types of vivax recurrences. Malaria elimination efforts need to address this largely undetected P. vivax transmission by simultaneously tackling the reservoir of P. falciparum and P. vivax infections.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2019
Language Anglais
Journal information "PLOS Medicine" - Vol. 16, no.5, p. e1002784 (2019)
Peer reviewed yes
Publisher Public Library of Science (PLoS)
e-issn 1549-1676
Publication status Publié
Affiliation UCL - SSS/IRSS - Institut de recherche santé et société
Keywords General Medicine
Links
  1. Guerra Carlos A., Howes Rosalind E., Patil Anand P., Gething Peter W., Van Boeckel Thomas P., Temperley William H., Kabaria Caroline W., Tatem Andrew J., Manh Bui H., Elyazar Iqbal R. F., Baird J. Kevin, Snow Robert W., Hay Simon I., The International Limits and Population at Risk of Plasmodium vivax Transmission in 2009, 10.1371/journal.pntd.0000774
  2. Baird J. Kevin, Maguire Jason D., Price Ric N., Diagnosis and Treatment of Plasmodium vivax Malaria, Advances in Parasitology (2012) ISBN:9780123979001 p.203-270, 10.1016/b978-0-12-397900-1.00004-9
  3. Fleming M. FDA Approves Tafenoquine, First New P Vivax Malaria Treatment in 60 Years. Contagion Live. JUL 23, 2018 [cited 2018 Aug 16]. https://www.contagionlive.com/news/fda-approves-tafenoquine-first-new-treatment-of-p-vivax-malaria-in-60-years.
  4. Baird J. Kevin, Resistance to Chloroquine Unhinges Vivax Malaria Therapeutics, 10.1128/aac.01296-10
  5. John George K, Douglas Nicholas M, von Seidlein Lorenz, Nosten Francois, Baird J, White Nicholas J, Price Ric N, Primaquine radical cure of Plasmodium vivax: a critical review of the literature, 10.1186/1475-2875-11-280
  6. WHO. Guidelines for the treatment of malaria. Third edition. April 2015 [cited 2018 Mar 10]. http://www.who.int/malaria/publications/atoz/9789241549127/en/.
  7. WHO. World Malaria Report 2017 [cited 2018 Aug 16]. http://apps.who.int/iris/bitstream/handle/10665/259492/9789241565523-eng.pdf;jsessionid=0F04E7242F1B3AEFFCF70870D09674A1?sequence=1.
  8. The Government of Vietnam. National Strategy for malaria control and elimination 2011–2020 and orientation for 2030. Decision No. 1920/QĐ-TTg dated of 27 October 2011 of the Prime Minister [cited 2017 Dec 21]. http://www.wpro.who.int/vietnam/topics/malaria/vnm_national_strategy_for_malaria_controlnelimination.pdf.
  9. National Malaria Control and Elimination Program (NMECP) in Vietnam. Malaria report from 2011 to 2015, Intenal Report. NIMPE, Hanoi 2016.
  10. National Malaria Control and Elimination Program (NMECP) in Vietnam. Malaria report from 1999 to 2016, Internal Report. NIMPE, Hanoi. 2016.
  11. Vietnam Ministry of Health: Guideline Surveillance and prevention of malaria disease. Hanoi, 2016 [cited 2017 Dec 21]. http://vncdc.gov.vn/files/Notice/2016/3/quyet-dinh-741_qdbyt-ngay-0232016-huong-dan-giam-sat-va-phong-chong-sot-ret(2).pdf.
  12. Cao Jun, Sturrock Hugh J. W., Cotter Chris, Zhou Shuisen, Zhou Huayun, Liu Yaobao, Tang Linhua, Gosling Roly D., Feachem Richard G. A., Gao Qi, Communicating and Monitoring Surveillance and Response Activities for Malaria Elimination: China's “1-3-7” Strategy, 10.1371/journal.pmed.1001642
  13. Ministry of Health. Guideline of diagnosis, treatment and prevention malaria disease 2016 [cited 2017 Dec 25]. https://thuvienphapluat.vn/van-ban/The-thao-Y-te/Quyet-dinh-4845-QD-BYT-Huong-dan-chan-doan-dieu-tri-benh-Sot-ret-2016-321533.aspx.
  14. Ministry of Health. Guideline of diagnosis, treatment and prevention malaria disease 2007 [cited 2017 Dec 25]. https://thuvienphapluat.vn/van-ban/The-thao-Y-te/Quyet-dinh-339-QD-BYT-Huong-dan-chuan-doan-dieu-tri-benh-sot-ret-93442.aspx.
  15. Ministry of Health. Guideline of diagnosis, treatment and prevention malaria disease 2009 [cited 2017 Dec 25]. https://vanbanphapluat.co/quyet-dinh-3232-qd-byt-2013-huong-dan-chan-doan-dieu-tri-benh-sot-ret.
  16. Thanh PV. Epidemiology of Plasmodium vivax malaria in Central Vietnam, PhD thesis 2018 [cited 2018 Oct 10]. https://dial.uclouvain.be/pr/boreal/en/object/boreal%3A202970.
  17. Grietens Koen Peeters, Soto Veronica, Toomer Elizabeth, D'Alessandro Umberto, Cuentas Alejandro Llanos, Erhart Annette, Gamboa Dionicia, Montalvo Tanilu Grande, Tenorio Alex, Ribera Joan Muela, Rodriguez Hugo, Adherence to 7-Day Primaquine Treatment for the Radical Cure of P. vivax in the Peruvian Amazon, 10.4269/ajtmh.2010.09-0521
  18. Douglas Nicholas M., Poespoprodjo Jeanne Rini, Patriani Dewi, Malloy Michael J., Kenangalem Enny, Sugiarto Paulus, Simpson Julie A., Soenarto Yati, Anstey Nicholas M., Price Ric N., Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study, 10.1371/journal.pmed.1002379
  19. Thanh Pham Vinh, Van Hong Nguyen, Van Van Nguyen, Van Malderen Carine, Obsomer Valérie, Rosanas-Urgell Anna, Grietens Koen Peeters, Xa Nguyen Xuan, Bancone Germana, Chowwiwat Nongnud, Duong Tran Thanh, D’Alessandro Umberto, Speybroeck Niko, Erhart Annette, Epidemiology of forest malaria in Central Vietnam: the hidden parasite reservoir, 10.1186/s12936-015-0601-y
  20. Garros Claire, Van Nguyen Cam, Trung Ho, Van Bortel Wim, Coosemans Marc, Manguin Sylvie, Distribution of Anopheles in Vietnam, with particular attention to malaria vectors of the Anopheles minimus complex, 10.1186/1475-2875-7-11
  21. Van Bortel Wim, Trung Ho Dinh, Hoi Le Xuan, Van Ham Nguyen, Van Chut Nguyen, Luu Nguyen Dinh, Roelants Patricia, Denis Leen, Speybroeck Niko, D'Alessandro Umberto, Coosemans Marc, Malaria transmission and vector behaviour in a forested malaria focus in central Vietnam and the implications for vector control, 10.1186/1475-2875-9-373
  22. Okell Lucy C., Bousema Teun, Griffin Jamie T., Ouédraogo André Lin, Ghani Azra C., Drakeley Chris J., Factors determining the occurrence of submicroscopic malaria infections and their relevance for control, 10.1038/ncomms2241
  23. Rubio J.M., Post R.J., van Leeuwen W.M.Docters, Henry M.-C., Lindergard G., Hommel M., Alternative polymerase chain reaction method to identify Plasmodium species in human blood samples: the semi-nested multiplex malaria PCR (SnM-PCR), 10.1016/s0035-9203(02)90077-5
  24. Eede Peter Van den, Van Hong Nguyen, Van Overmeir Chantal, Vythilingam Indra, Duc Thang Ngo, Hung Le Xuan, Manh Hung Nguyen, Anné Jozef, D'Alessandro Umberto, Erhart Annette, Human Plasmodium knowlesi infections in young children in central Vietnam, 10.1186/1475-2875-8-249
  25. Nguyen Hong Van, Eede Peter van den, van Overmeir Chantal, Thang Ngo Duc, Hung Le Xuan, D'Alessandro Umberto, Erhart Annette, Marked Age-Dependent Prevalence of Symptomatic and Patent Infections and Complexity of Distribution of Human Plasmodium Species in Central Vietnam, 10.4269/ajtmh.2012.12-0047
  26. Tien NT. Reviewing the monitoring of antimalarial drug efficacy and resistance in sentinel sites in Vietnam. International Colloquium ITM/NIMPE 2007 [cited 2017 Dec 21]. Abstract book p. 71 [71]. https://studylib.net/doc/8823884/abstract-book.
  27. Amorim Leila DAF, Cai Jianwen, Modelling recurrent events: a tutorial for analysis in epidemiology, 10.1093/ije/dyu222
  28. Cleves M. Analysis of multiple failure-time survival data [cited 2017 Dec 21]. http://www.stata.com/support/faqs/statistics/multiple-failure-time-data/.
  29. WHO. Status report on artemisinin resistance and ACT efficacy (August 2018) 2018 [cited 2018 Aug 16]. https://www.who.int/malaria/publications/atoz/artemisinin-resistance-august2018/en/.
  30. National Malaria Control and Elimination Program (NMECP) in Vietnam. Annual Malaria report, Internal report. NIMPE, Hanoi. 2018.
  31. National Malaria Control and Elimination Program (NMECP) in Vietnam. Annual Malaria report, Internal report. NIMPE, Hanoi. 2017.
  32. Phuc Bui Quang, Rasmussen Charlotte, Duong Tran Thanh, Dong Le Than, Loi Mai Anh, Ménard Didier, Tarning Joel, Bustos Dorina, Ringwald Pascal, Galappaththy Gawrie Loku, Thieu Nguyen Quang, Treatment Failure of Dihydroartemisinin/Piperaquine for Plasmodium falciparum Malaria, Vietnam, 10.3201/eid2304.161872
  33. Thriemer Kamala, Bobogare Albino, Ley Benedikt, Gudo Clarice Samo, Alam Mohammad Shafiul, Anstey Nick M., Ashley Elizabeth, Baird J. Kevin, Gryseels Charlotte, Jambert Elodie, Lacerda Marcus, Laihad Ferdinand, Marfurt Jutta, Pasaribu Ayodhia Pitaloka, Poespoprodjo Jeanne Rini, Sutanto Inge, Taylor Walter R., van den Boogaard Christel, Battle Katherine E., Dysoley Lek, Ghimire Prakash, Hawley Bill, Hwang Jimee, Khan Wasif Ali, Mudin Rose Nani Binti, Sumiwi Maria Endang, Ahmed Rukhsana, Aktaruzzaman M. M., Awasthi Kiran Raj, Bardaji Azucena, Bell David, Boaz Leonard, Burdam Faustina Helen, Chandramohan Daniel, Cheng Qin, Chindawongsa Keobouphaphone, Culpepper Janice, Das Santasabuj, Deray Raffy, Desai Meghna, Domingo Gonzalo, Duoquan Wang, Duparc Stephan, Floranita Rustini, Gerth-Guyette Emily, Howes Rosalind E., Hugo Cecilia, Jagoe George, Sariwati Elvieda, Jhora Sanya Tahmina, Jinwei Wu, Karunajeewa Harin, Kenangalem Enny, Lal Bibek Kumar, Landuwulang Chandra, Le Perru Emmanuel, Lee Sang-Eun, Makita Leo Sora, McCarthy James, Mekuria Asrat, Mishra Neelima, Naket Esau, Nambanya Simone, Nausien Johnny, Duc Thang Ngo, Thi Thuan Nguyen, Noviyanti Rinitis, Pfeffer Daniel, Qi Gao, Rahmalia Annisa, Rogerson Stephen, Samad Iriani, Sattabongkot Jetsumon, Satyagraha Ari, Shanks Dennis, Sharma Surender Nath, Sibley Carol Hopkins, Sungkar Ali, Syafruddin Din, Talukdar Arunansu, Tarning Joel, ter Kuile Feiko, Thapa Suman, Theodora Minerva, Huy Tho Tran, Waramin Edward, Waramori Govert, Woyessa Adugna, Wongsrichanalai Chansuda, Xa Nguyen Xuan, Yeom Joon Sup, Hermawan Lukas, Devine Angela, Nowak Spike, Jaya Indra, Supargiyono Supargiyono, Grietens Koen Peeters, Price Ric N., Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group, 10.1186/s12936-018-2380-8
  34. Medicines for Malaria Venture (MMV). Tafenoquine 2018 [cited 2018 Oct 20]. https://www.mmv.org/related-story-type/tafenoquine.
  35. Nguyen Thuy-Nhien, von Seidlein Lorenz, Nguyen Tuong-Vy, Truong Phuc-Nhi, Hung Son Do, Pham Huong-Thu, Nguyen Tam-Uyen, Le Thanh Dong, Dao Van Hue, Mukaka Mavuto, Day Nicholas PJ, White Nicholas J, Dondorp Arjen M, Thwaites Guy E, Hien Tran Tinh, The persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium vivax infections over time in Vietnam: an open cohort study, 10.1016/s1473-3099(18)30046-x
  36. SATTABONGKOT JETSUMON, PHUNKITCHAR VICHIT, MANEECHAI NONGNUJ, COLEMAN RUSSELL E., KHUNTIRAT BENJAWAN, EIKARAT NANTANA, BURGE ROBERT, SIRICHAISINTHOP JEERAPHAT, COMPARISON OF ARTIFICIAL MEMBRANE FEEDING WITH DIRECT SKIN FEEDING TO ESTIMATE THE INFECTIOUSNESS OF PLASMODIUM VIVAX GAMETOCYTE CARRIERS TO MOSQUITOES, 10.4269/ajtmh.2003.69.529
  37. COLLINS WILLIAM E., JEFFERY GEOFFREY M., ROBERTS JACQUELIN M., A RETROSPECTIVE EXAMINATION OF THE EFFECT OF FEVER AND MICROGAMETOCYTE COUNT ON MOSQUITO INFECTION ON HUMANS INFECTED WITH PLASMODIUM VIVAX, 10.4269/ajtmh.2004.70.638
  38. Cheng Qin, Cunningham Jane, Gatton Michelle L., Systematic Review of Sub-microscopic P. vivax Infections: Prevalence and Determining Factors, 10.1371/journal.pntd.0003413
  39. JA Sinton, Indian J Malariol, 9, 229 (1955)
  40. White Nicholas J, Determinants of relapse periodicity in Plasmodium vivax malaria, 10.1186/1475-2875-10-297
  41. Douglas N. M., Nosten F., Ashley E. A., Phaiphun L., van Vugt M., Singhasivanon P., White N. J., Price R. N., Plasmodium vivax Recurrence Following Falciparum and Mixed Species Malaria: Risk Factors and Effect of Antimalarial Kinetics, 10.1093/cid/ciq249
  42. Looareesuwan Sornchai, White NicholasJ., Bunnag Danai, Chittamas Sunee, Harinasuta Tranakchit, HIGH RATE OF PLASMODIUM VIVAX RELAPSE FOLLOWING TREATMENT OF FALCIPARUM MALARIA IN THAILAND, 10.1016/s0140-6736(87)91479-6
  43. Price Ric N., Douglas Nicholas M., Anstey Nicholas M., von Seidlein Lorenz, Plasmodium vivax treatments : what are we looking for?, 10.1097/qco.0b013e32834c61e3
  44. Thanh Pham Vinh, Hong Nguyen Van, Van Nguyen Van, Louisa Melva, Baird Kevin, Xa Nguyen Xuan, Peeters Grietens Koen, Hung Le Xuan, Duong Tran Thanh, Rosanas-Urgell Anna, Speybroeck Niko, D'Alessandro Umberto, Erhart Annette, Confirmed Plasmodium vivax Resistance to Chloroquine in Central Vietnam, 10.1128/aac.00791-15
  45. Betuela Inoni, Rosanas-Urgell Anna, Kiniboro Benson, Stanisic Danielle I., Samol Lornah, de Lazzari Elisa, del Portillo Hernando A., Siba Peter, Alonso Pedro L., Bassat Quique, Mueller Ivo, Relapses Contribute Significantly to the Risk of Plasmodium vivax Infection and Disease in Papua New Guinean Children 1–5 Years of Age, 10.1093/infdis/jis580
  46. WHO. Guidelines for the treatment of malaria. Second Edition. 2010 [cited 2017 Dec 21]. http://apps.who.int/medicinedocs/documents/s19105en/s19105en.pdf.]
  47. Baird J. K., Hoffman S. L., Primaquine Therapy for Malaria, 10.1086/424663
  48. N Gogtay, Cochrane Database Syst Rev, CD008492 (2013)
  49. Douglas Nicholas M, Anstey Nicholas M, Angus Brian J, Nosten Francois, Price Ric N, Artemisinin combination therapy for vivax malaria, 10.1016/s1473-3099(10)70079-7
  50. Mugenyi L, Herzog SA, Hens N, Abrams S. Modelling longitudinal binary outcomes with outcome- dependent observation times: an application to a malaria cohort study. BioRxiv 252411 [Preprint]. 2018 [cited 2018 Oct 30]. https://www.biorxiv.org/content/10.1101/252411v1.
Bibliographic reference Pham, Thanh Vinh ; Nguyen, Hong Van ; Rosas Aguirre, Angel ; Nguyen, Van Van ; A. Cleves, Mario ; et. al. Plasmodium vivax morbidity after radical cure: A cohort study in Central Vietnam. In: PLOS Medicine, Vol. 16, no.5, p. e1002784 (2019)
Permanent URL http://hdl.handle.net/2078.1/216739